Carrying TB Without Knowing It: Understanding Latent Infection and Why Treatment Cannot Wait

Most Americans associate tuberculosis with a dramatic, unmistakable illness—a persistent cough, weight loss, night sweats, the kind of symptoms that send a person to the emergency room. What far fewer people understand is that for millions of individuals across the country, tuberculosis exists in a form that produces none of these signs at all. It is present, it is real, and it is capable of becoming active at any point in a person's life—yet it offers no warning and causes no immediate harm.

This is latent tuberculosis infection, and it is one of the most underappreciated public health challenges in the United States today.

What Is Latent TB Infection?

When a person inhales Mycobacterium tuberculosis—the bacterium responsible for TB—their immune system typically mounts a response capable of containing, though not eliminating, the pathogen. The bacteria are effectively walled off within the lungs and other tissues, remaining alive but inactive. This state is known as latent TB infection, or LTBI.

Individuals with LTBI are not sick. They cannot transmit the infection to others. They experience no symptoms. Without testing, they have no way of knowing the infection exists. Yet the bacteria persist, and under the right—or rather, the wrong—circumstances, they can reactivate, multiplying rapidly and producing the full, contagious form of the disease known as active TB.

The distinction between latent and active TB is therefore not merely clinical; it is epidemiological. Active TB is a public health emergency requiring immediate isolation and treatment. Latent TB is a preventable future emergency—one that, with proper identification and intervention, need never materialize.

The Scale of the Problem in America

The Centers for Disease Control and Prevention estimates that between 5 and 10 million people in the United States are currently living with latent TB infection. This figure, while striking, reflects the cumulative result of decades of immigration from countries with higher TB prevalence, as well as domestic transmission patterns that have never been fully interrupted.

Approximately 5 to 10 percent of individuals with untreated LTBI will develop active TB at some point during their lifetime. That risk is not uniformly distributed. For individuals whose immune systems become compromised—whether due to HIV infection, diabetes, cancer treatment, the use of immunosuppressive medications such as TNF-alpha inhibitors, or simply the natural aging process—the probability of reactivation is substantially higher. People living with HIV who also carry LTBI face a risk of progression to active disease that is estimated to be 20 to 30 times greater than that of immunocompetent individuals.

These numbers translate into preventable suffering. Each year, a meaningful proportion of new active TB cases in the United States arise not from recent transmission but from reactivation of latent infections that were never identified or treated. Addressing LTBI is, in this sense, inseparable from the broader goal of reducing TB incidence in America.

Who Should Be Tested?

Current guidance from the CDC and the United States Preventive Services Task Force recommends targeted testing for latent TB infection in populations at elevated risk. These include:

• Foreign-born individuals from countries with high TB prevalence, including many nations in sub-Saharan Africa, Southeast Asia, Eastern Europe, and Latin America
• People living with HIV
• Individuals who have had close contact with a confirmed active TB case
• Residents and staff of congregate settings, including correctional facilities, homeless shelters, and long-term care facilities
• Healthcare workers with occupational exposure to TB patients
• People with certain medical conditions that suppress immune function, including those receiving dialysis, preparing for organ transplantation, or initiating biologic therapies
• Individuals experiencing homelessness or unstable housing

Testing for LTBI is performed through one of two methods: the tuberculin skin test (TST), which involves a small injection under the skin and requires a follow-up visit 48 to 72 hours later to read the result, or the interferon-gamma release assay (IGRA), a blood test that requires only a single visit and is generally preferred for individuals who have received the BCG vaccine, as it produces fewer false-positive results in this population.

Neither test can distinguish between latent and active TB; a positive result indicates infection with M. tuberculosis and requires follow-up evaluation, including chest radiography and clinical assessment, to rule out active disease before LTBI treatment is initiated.

Modern Treatment: Shorter, More Effective, Better Tolerated

For many years, the standard treatment for latent TB infection was a nine-month course of daily isoniazid—a regimen that, while effective, was associated with significant rates of non-completion due to its length and the risk of drug-induced liver injury. Completion rates for this regimen historically hovered around 50 to 60 percent in many clinical settings, leaving a substantial proportion of patients with untreated LTBI despite having been identified.

The past decade has brought meaningful advances in LTBI treatment that are improving outcomes and encouraging broader uptake. Two regimens in particular have transformed clinical practice:

• 3HP (Three months of weekly isoniazid and rifapentine): This 12-dose regimen, administered once weekly under direct observation or as self-administered therapy, has demonstrated efficacy comparable to nine months of daily isoniazid with substantially higher completion rates—in some studies exceeding 85 percent. Its shorter duration reduces the burden on patients and providers alike.

• 4R (Four months of daily rifampin): This regimen offers an alternative for patients who cannot tolerate isoniazid, with clinical trials demonstrating non-inferior efficacy and a favorable safety profile.

These shorter regimens represent a genuine breakthrough in LTBI management. By reducing the treatment period from nine months to three or four, they meaningfully lower the barrier to completion—a factor that is at least as important as efficacy in determining real-world public health impact.

Real Consequences, Real People

The clinical and statistical dimensions of latent TB infection are important, but they can obscure the human reality of what is at stake. Consider a 52-year-old construction worker from El Salvador who immigrated to the United States in his twenties, was never screened for LTBI, and was diagnosed with active pulmonary TB after beginning treatment for rheumatoid arthritis with a biologic medication that suppressed his immune response. His case required six months of intensive treatment, temporary disability, and contact investigation of his coworkers and family members.

Or consider a 38-year-old woman who learned she had LTBI during routine screening at a community health center and completed a 3HP regimen over three months. She experienced no serious side effects, required no hospitalization, and—more than a decade later—has never developed active disease.

The difference between these two trajectories is not luck. It is access to screening, a knowledgeable provider, and a treatment regimen she could realistically complete.

The Role of Early Intervention

Latent TB infection is, by definition, asymptomatic. It will not announce itself. It will not prompt an urgent care visit or generate a chief complaint. Identifying it requires intentional, systematic screening in populations known to carry elevated risk—and it requires healthcare systems that are equipped and motivated to act on positive results.

The StopTB Initiative encourages medical providers to incorporate LTBI screening into routine care for at-risk patients and to familiarize themselves with the full range of modern treatment options now available. We encourage individuals in higher-risk groups to discuss TB testing with their healthcare provider—not out of alarm, but out of informed self-advocacy.

A latent infection left unaddressed is not a stable situation. It is a deferred risk. With the tools now available to identify and treat LTBI effectively, there is no reason that risk must ever be realized.